Ratiopharm up for grabs
This article was originally published in The Tan Sheet
The Merckle Group, the parent of German OTC and generic drug firm Ratiopharm, agrees with investors at VEM VV GmbH to arrange for a bridge loan from Merckle's creditor banks in order to sell Ratiopharm. The Jan. 7 decision follows the suicide of Merckle Group founder, Adolf Merckle, which was linked to his and the company's financial crises. The sale likely will take several months, Ratiopharm says
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.